Cencora Inc
NYSE:COR

Watchlist Manager
Cencora Inc Logo
Cencora Inc
NYSE:COR
Watchlist
Price: 227.69 USD 0.63% Market Closed
Market Cap: 44B USD
Have any thoughts about
Cencora Inc?
Write Note

Cencora Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cencora Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Cencora Inc
NYSE:COR
Additional Paid In Capital
$6B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
8%
Cardinal Health Inc
NYSE:CAH
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Henry Schein Inc
NASDAQ:HSIC
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Adapthealth Corp
NASDAQ:AHCO
Additional Paid In Capital
$2.2B
CAGR 3-Years
2%
CAGR 5-Years
275%
CAGR 10-Years
N/A
Patterson Companies Inc
NASDAQ:PDCO
Additional Paid In Capital
$272m
CAGR 3-Years
14%
CAGR 5-Years
14%
CAGR 10-Years
59%
Mckesson Corp
NYSE:MCK
Additional Paid In Capital
$8.2B
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
2%
No Stocks Found

Cencora Inc
Glance View

Market Cap
44.4B USD
Industry
Health Care
Economic Moat
None

Cencora Inc., once known as AmerisourceBergen, stands as a pivotal player in the healthcare landscape, sculpting pathways for the seamless distribution of pharmaceuticals across the globe. Born from a merger of AmeriSource Health Corporation and Bergen Brunswig Corporation in 2001, the company carved its identity by building extensive networks that bind drug manufacturers, pharmacies, and healthcare providers together into a cohesive chain. This intricate web ensures that pharmaceutical products, ranging from common prescriptions to specialized drugs, reach their destinations efficiently and securely. Cencora's proficiency lies not just in logistics but in its ability to adapt and innovate within rigid regulatory frameworks, ensuring its clients navigate the complexities of compliance while focusing on patient care. In terms of profitability, Cencora thrives on its vast and exponentially growing distribution channels, earning a steady stream of revenue through service fees and percentage fees tied to the value of distributed goods. Moreover, the company's integrated service offerings, such as consulting, analytics, and supply chain management solutions, provide additional avenues of income by addressing the strategic needs of its clientele. This dual approach of logistics and consultancy allows Cencora not only to serve as a conduit for drug distribution but also as a trusted advisor in a healthcare sphere that is increasingly data-driven and efficiency-focused. Through its multi-faceted business model, Cencora secures its foundation in a volatile industry, supporting the balance of patient needs, market demands, and regulatory compliance.

COR Intrinsic Value
487.88 USD
Undervaluation 53%
Intrinsic Value
Price

See Also

What is Cencora Inc's Additional Paid In Capital?
Additional Paid In Capital
6B USD

Based on the financial report for Sep 30, 2024, Cencora Inc's Additional Paid In Capital amounts to 6B USD.

What is Cencora Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
8%

Over the last year, the Additional Paid In Capital growth was 3%. The average annual Additional Paid In Capital growth rates for Cencora Inc have been 3% over the past three years , 4% over the past five years , and 8% over the past ten years .

Back to Top